LYSOSOMAL STORAGE DISEASES AND CARDIOVASCULAR SYSTEM (REVIEW ARTICLE)
DOI:
https://doi.org/10.52914/apmp.v6i1.72Keywords:
lysosomal storage disease, mucopolysaccharidosis, cardiovascular system, diagnostics, treatmentAbstract
The analysis of literature data reflecting the issues of the pathology of the cardiovascular system in mucopolysaccharidosis are presented. It was found out that heart and vessels damage is one of the cardinal signs of this pathology, often leading to death. Cardiac pathology is recorded in all types of mucopolysaccharidosis, but it is most significant for patients with three clinical variants of Hurler syndrome, Hunter, and Maroteaux–Lamy syndromes. Typical signs of damage to the cardiovascular system in mucopolysaccharidosis are thickening of the valves with the development of their dysfunction (while the severity of damage to the left-sided valves is more pronounced), myocardial hypertrophy, conduction disturbance, coronary artery disease, arterial hypertension. Many researchers emphasize the difficulties of clinical and functional examination of the cardiovascular system in patients with mucopolysaccharidosis, which is due to the presence of physical and intellectual limitations in patients, ands a gradual increase in symptoms. For the treatment of cardiovascular pathology at mucopolysaccharidosis, medical and surgical methods are used, including enzyme replacement therapy and stem cell transplantation.
References
McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021. Vol. 42. No. 36. P. 3599-3726. DOI: https://doi.org/10.1093/eurheartj/ehab368 DOI: https://doi.org/10.1093/eurheartj/ehab368
Williams K.B., Brigatti K.W., Puffenberger E.G. et al. Homozygosity for a mutation affecting the catalytic domain of tyrosyl-tRNA synthetase (YARS) causes multisystem disease. Human Molecular Genetic. 2019. Vol. 28. No. 4. P. 525-538. DOI: https://doi.org/10.1093/hmg/ddy344 DOI: https://doi.org/10.1093/hmg/ddy344
Viskochil D., Clarke L., Bay L., et al. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry AJMG. 2019. Vol. 179. No. 12. P. 2425-2432. DOI: https://doi.org/10.1002/ajmg.a.61378 DOI: https://doi.org/10.1002/ajmg.a.61378
Tomanin R., Karageorgos L., Zanetti А. et al. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene. Human Mutation. 2018. Vol. 39. No. 12. P. 1788-1802. DOI: https://doi.org/10.1002/humu.23613 DOI: https://doi.org/10.1002/humu.23613
Parini R., Deodato F., Rocco M.D., et al. Open issues in Mucopolysaccharidosis type I-Hurler Orphanet Journal Rare Diseases. 2017. Vol. 15. No. 12(1). P. 112-117. DOI: https://doi.org/10.1186/s13023-017-0662-9. DOI: https://doi.org/10.1186/s13023-017-0662-9
Krovetz L.J., Lorincz A.E., Schiebler G.L. Cardiovascular manifestations of the Hurler syndrome. Hemodynamic andangiocardiographic observations in 15 patients. Circulation. 1965. Vol. 31. P. 132-141. DOI: https://doi.org/10.1161/01.cir.31.1.132. DOI: https://doi.org/10.1161/01.CIR.31.1.132
Renteria V.G., Ferrans V.J., Roberts W.C. The heart in theHurler syndrome. Gross, histologic and ultrastructuralobservations in five necropsy cases. American Journal Cardiology. 1976; Vol. 38. No. 4. P. 487-501. URL: https://www.ajconline.org/article/0002-9149(76)90468-9/abstract DOI: https://doi.org/10.1016/0002-9149(76)90468-9
Ayuna A., Stepien K.L., Hendriksz C.H. et al. Cardiac rhythm abnormalities - An underestimated cardiovascular risk in adult patients with Mucopolysaccharidoses. Mol. Genet. Metab. 2020. Vol. 130. No. 2. P. 133-139. DOI: https://doi.org/ 10.1016/ j.ymgme.2020.03.005 DOI: https://doi.org/10.1016/j.ymgme.2020.03.005
Chen M.R., Lin S.P., Hwang H.K., et al. Cardiovascularchanges in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005. Vol. 60. No. 1. P. 51-53. URL: https://pubmed.ncbi.nlm.nih.gov/ 15779852/ DOI: https://doi.org/10.2143/AC.60.1.2005049
Poletto E., Baldo G., Gomez-Ospina N. Genome Editing for Mucopolysaccharidoses. Int. J. Mol. Sci. 2020. Vol. 13, No. 21(2). P. 500-509. DOI: https://doi.org/10.3390/ijms21020500 DOI: https://doi.org/10.3390/ijms21020500
Jones S.A., Almássy Z., Beck M. et al. Mortality and cause of death in mucopolysaccharidosis type II - a historical review based on data from the Hunter Outcome Survey (HOS). J. Inherit. Metab. Dis. 2009. Vol.32. No. 5. P. 534-543. DOI: https://doi.org/10.1007/s10545-009-1119-7. DOI: https://doi.org/10.1007/s10545-009-1119-7
Jameson E., Jones S. Remmington Enzyme replacement therapy with laronidase (Aldurazyme ®) for treating mucopolysaccharidosis type I Cochrane Database Syst. Rev. 2019. Vol. 18. No. 6(6). P. CD009354. DOI: https://doi.org/10.1002/14651858.CD009354.pub5. DOI: https://doi.org/10.1002/14651858.CD009354.pub5
Leal G.N., Paula A.C., Leone C., et al. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol. Young. 2010. Vol. 20. P. 254-261. DOI: https://doi.org/10.1017/S104795110999062X. DOI: https://doi.org/10.1017/S104795110999062X
Braunlin E., Steinberger J., DeFor T., et al. Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis Type I (Hurler Syndrome). Biol. Blood Marrow Transplant. 2018. Vol. 24. No. 6. P. 1289-1293. DOI:https://doi.org/10.1016/j.bbmt.2018.01.028. DOI: https://doi.org/10.1016/j.bbmt.2018.01.028
Hirth A., Berg A., Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J. Inherit. Metab. Dis. 2007. Vol. 30. No. 4. P. 820-834. DOI: https://doi.org/10.1007/s10545-007-0613-z. DOI: https://doi.org/10.1007/s10545-007-0613-z
Soliman O.II., Timmermans R.G.M., Nemes A. et al. Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. JIMD. 2007. Vol. 30. No. 5. P. 750-757. DOI: https://doi.org/10.1007/s10545-007-0586-y DOI: https://doi.org/10.1007/s10545-007-0586-y
Braunlin E.A., Harmatz P.R., Scarpa M. et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. JIMD. 2011. Vol. 34. No. 6. Р. 1183-1197. DOI: https://doi.org/10.1007/s10545-011-9359-8 DOI: https://doi.org/10.1007/s10545-011-9359-8
Harmatz P., Shediac R. Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment Front Biosci. (Landmark Ed). 2017. Vol. 1. No. 22. Р. 385-406. DOI: https://doi.org/10.2741/4490 DOI: https://doi.org/10.2741/4490
Thomas J.A., Beck M., Clarke J.T.R., Cox G.F. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. JIMD. 2010. Vol. 33. No. 4. P. 421-427. DOI: https://doi.org/10.1007/s10545-010-9113-7 DOI: https://doi.org/10.1007/s10545-010-9113-7
Wraith J.E., Beck M., Giugliani R. et al. Initial report from the Hunter Outcome Survey. Genet. Med. 2008. Vol. 10. P. 508-516. DOI: https://doi.org/10.1097/gim.0b013e31817701e6 DOI: https://doi.org/10.1097/GIM.0b013e31817701e6
Yano S., Moseley K., Pavlova Z. Postmortem studies on a patientwith mucopolysaccharidosis type I: Histopathological findingsafter one year of enzyme replacement therapy. JIMD. 2009. Vol. 32. No. S. P. 53-57. DOI: https://doi.org/10.1007/s10545-009-1057-4 DOI: https://doi.org/10.1007/s10545-009-1057-4
Johnson G.L., Vine D.L., Cottrill C.M., et al. Echocardiographic mitral valve deformity in the mucopolysaccharidoses. Pediatrics 1981. Vol. 67. P. 401-406. PMID: 6787559. URL: https://pubmed.ncbi.nlm.nih.gov/6787559/ DOI: https://doi.org/10.1542/peds.67.3.401
Maganti K., Rigolin V.H., Sarano M.E., et al. Valvular heart disease: diagnosis and management. Mayo Clin. Proc. 2010. Vol. 85. P. 483-500. DOI: https://doi.org/10.4065/mcp.2009.0706 DOI: https://doi.org/10.4065/mcp.2009.0706
Taylor M., Khan S., Stapleton M. et al. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biol. Blood. Marrow Transplant. 2019. Vol. 25. No. 7. P. e226-e246. URL: https://www.astctjournal.org/article/S1083-8791(19)30137-5/fulltext DOI: https://doi.org/10.1016/j.bbmt.2019.02.012
Kettles D.I., Sheppard M., Liebmann R.D., et al. Left ventricular aneurysm, aortic valve disease and coronary narrowing in a patient with Hunter’s syndrome. Cardiovasc Pathol. 2002. Vol. 11. Is. 2. P. 94-96. DOI: https://doi.org/10.1016/S1054-8807(01)00099-0 URL: https://pubmed.ncbi.nlm.nih.gov/11934600/ DOI: https://doi.org/10.1016/S1054-8807(01)00099-0
Braunlin E.A., Krivit W., Burke B.A. et al. Radiological case of the month. Arch. Pediatr. Adolesc. Med. 2000. Vol. 154. No. 8. P. 841-842. DOI: https://doi:10.1001/archpedi.154.8.841 DOI: https://doi.org/10.1001/archpedi.154.8.841
Burton B.K., Jego V., Mikl J. et al. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). JIMD. 2017. Vol. 40. No. 6: 867-874. DOI: https://doi.org/10.1007/s10545-017-0075-x DOI: https://doi.org/10.1007/s10545-017-0075-x
Giugliani R., Harmatz P., Wraith J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007. Vol. 120. P. 405-418. DOI: https://doi.org/10.1542/peds.2006-2184 DOI: https://doi.org/10.1542/peds.2006-2184
Nemes A., Timmermans R.G., Wilson J.H. et al. The mild form of mucopolysaccharidosis type I (Scheie syndrome) is associated with increased ascending aortic stiffness. Heart Vessels. 2008. Vol. 23. P. 108-111. DOI: https://doi.org/10.1007/s00380-007-1013-x DOI: https://doi.org/10.1007/s00380-007-1013-x
Hinek A., Wilson S.E. Impaired elastogenesis in Hurler disease. Dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am. J. Pathol. 2000. Vol. 156. P. 925-938. DOI: https://doi.org/10.1016/S0002-9440(10)64961-9 DOI: https://doi.org/10.1016/S0002-9440(10)64961-9
Ma X., Tittiger M., Knutsen R.H. et al. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol. Genet. Metab. 2008. Vol. 94. P. 298-304. DOI: https://doi.org/10.1016/j.ymgme.2008.03.018 DOI: https://doi.org/10.1016/j.ymgme.2008.03.018
Fesslová V., Corti P., Sersale G., et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol. Young. 2009. Vol. 19. No. 2. P. 170-178. DOI: https://doi.org/10.1017/S1047951109003576 DOI: https://doi.org/10.1017/S1047951109003576
Keller C., Briner J., Schneider J.. et al. Mucopolysaccharidosis 6-A (Maroteaux-Lamy disease): comparison of clinical and pathologico-anatomic findings in a 27-year-old patient. Helv Paediatr Acta 1987. Vol. 42. P. 317-333. PMID: 3127360 https://pubmed.ncbi.nlm.nih.gov/3127360/
Bush D., Sremba L., Lomax K. et al. Neonatal Onset Interstitial Lung Disease as a Primary Presenting Manifestation of Mucopolysaccharidosis Type I. JIMD. 2019. Vol. 43. Р. 71-77. URL: https://pubmed.ncbi.nlm.nih.gov/29654546/ https://link.springer.com/chapter/10.1007/8904_2018_101 DOI: https://doi.org/10.1007/8904_2018_101
Hishitani T., Wakita S., Isoda T. et al. Sudden death in Hunter syndrome caused by complete atrioventricular block. J. Pediatr. 2000. Vol. 136. Is. 2. P. 268-269. DOI: https://doi.org/ 10.1016/s0022-3476(00)70117-x URL: https://www.jpeds.com/article/S0022-3476(00)70117-X/abstract DOI: https://doi.org/10.1016/S0022-3476(00)70117-X
Gupta V., Barzilla J.E., Mendez J.S. et al. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc. Pathol. 2009. Vol. 18. No. 4. Р. 191-197. DOI: https://doi.org/10.1016/j.carpath.2008.05.001 DOI: https://doi.org/10.1016/j.carpath.2008.05.001
Latif N., Sarathchandra P., Taylor P.M. et al. Localization and pattern of expression of extracellular matrix components in human heart valves. J. Heart Valve Dis. 2005. Vol. 14. P. 218-227. URL: https://pubmed.ncbi.nlm.nih.gov/15792183/
Grande-Allen K.J., Griffin B.P., Ratliff N.B. et al. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations. J. Am. Coll. Cardiol. 2003. Vol. 42. Vol. 2. P. 271-277. DOI: https://doi.org/10.1016/S0735-1097(03)00626-0 DOI: https://doi.org/10.1016/S0735-1097(03)00626-0
Nakashima Y., Wight T.N., Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc. Res. 2008. Vol. 79. P. 14-23. DOI: https://doi.org/10.1093/cvr/cvn099 DOI: https://doi.org/10.1093/cvr/cvn099
Braunlin E., Tolar J., Mackey-Bojack S. et al. Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (Hurler syndrome) are activated valvular interstitial cells. Cardiovasc. Pathol. 2011. Vol. 20. No. 5. P. 315-321. DOI: https://doi.org/10.1016/j.carpath.2010.06.004 DOI: https://doi.org/10.1016/j.carpath.2010.06.004
Theocharis A.D., Tsolakis I., Hjerpe A., et al. Versican undergoes specific alterations in the fine molecular structure and organization in human aneurysmal abdominal aortas. Biomed. Chromatogr. 2003. Vol. 17. No. 6. P. 411-416. DOI: https://doi.org/10.1002/bmc.263 DOI: https://doi.org/10.1002/bmc.263
Simonaro C.M. Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycanmediated inflammation. JPRM. 2010. Vol. 3. No. 2. P. 85-88. DOI: https://doi.org/10.3233/PRM-2010-0120 DOI: https://doi.org/10.3233/PRM-2010-0120
Mathew R.C., Löffler A.I., Salerno M. Role of Cardiac Magnetic Resonance Imaging in Valvular Heart Disease: Diagnosis, Assessment, and Management. Curr. Cardiol. Rep. 2018. Vol. 26. No. 20 (11). P. 119. DOI: https://doi.org/10.1007/s11886-018-1057-9 DOI: https://doi.org/10.1007/s11886-018-1057-9
Wolk M.J., Bailey S.R., Doherty J.U. et al. ACCF/ SCCT/ ACR/ AHA/ ASE/ ASNC/ NASCI/ SCAI/SCMR 2013 appropriateuse criteria for cardiac computed tomography. A report of theAmerican College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the AmericanHeart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the NorthAmerican Society for Cardiovascular Imaging, the Society forCardiovascular Angiography and Interventions, and the Societyfor Cardiovascular Magnetic Resonance. J. Am. Coll. Cardiol. 2014. Vol. 63. No. 4. P. 380-406. DOI: https://doi.org/10.1016/j.jacc.2013.11.009 DOI: https://doi.org/10.1016/j.jacc.2013.11.009
Kakkis E., Marsden D. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Mol. Genet. Metab. 2020. Vol. 130. No. 2. P. 7-15. DOI: https://doi.org/10.1016/j.ymgme.2020.02.006 DOI: https://doi.org/10.1016/j.ymgme.2020.02.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sergiy Pyvovar, Iurii Rudyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
